🇺🇸 FDA
Patent

US 12018261

Compounds and methods for modulating factor XII

granted A61PA61P7/02A61P7/10

Quick answer

US patent 12018261 (Compounds and methods for modulating factor XII) held by Ionis Pharmaceuticals, Inc. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
58
CPC classes
A61P, A61P7/02, A61P7/10, A61P9/10